Hydrogen Peroxide

-Carbonium Merger Remains on Track-European Regulatory Expansion and Partnership Growth-Advancement of Biosafety Cabinet Standards -Defense Sector Growth FREDERICK, Md., July 29, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today reaffirmed its expectation to achieve revenue of at least $12 million in 2026. This is driven by strong first half trends, an increase of over 100% in sales and receipt of sales as compared to 2025, which has already exceeded the full 2025 year sales. Currently TOMI has secured over $6.2 million in booked orders and orders that are expected to be completed before year-end. Further, approximately $8.6 million of the Company’s current $35 million sales pipeline is in advanced stages. The Company remains actively engaged with Carbonium Core following the signing of the definitive merger agreement, as we continue to work toward closing of the transaction in the second half of 2026. As previously announced, with the support of federal and state government, including the U.S. Department of Energy, Carbonium is conducting a pilot study to produce nuclear-grade graphite for 4th-generation nuclear reactors and plans to move to full-scale commercial production, and we look forward to the completion of the merger which we believe will significantly enhance the value and financial performance of our company. In the second quarter of 2026, all four key metrics, BIT Solution sales, mobile equipment sales, single applicator sales and support services, showed both year-over-year and sequential growth. The increases in applicator sales and support services are primarily due to initiatives implemented in late 2024 and early 2025. The Company continues to pursue new growth markets, including robotaxis, biosecurity, drones and humanoid robotics. International sales continue to be an expanding opportunity for the Company. TOMI’s innovative disinfection product is now approved for use in Austria, Italy, the Netherlands, Belgium, Denmark, Germany, Hungary, Spain, Great Britain, and Northern Ireland. We added in Switzerland through an amendment and anticipate receiving approvals in France, Switzerland, Ireland, Poland, Portugal, and Romania. TOMI’s recent expansion of SteraMist registrations across the European Union has significantly strengthened the Company’s established European network. In Poland, our partnership with MedLine will soon be able to successfully market SteraMist under the DeconLine brand once mutual recognition is approved. Additionally, TOMI has deepened its commercial pipelines through dedicated partners in Germany, the United Kingdom, and the Netherlands, many of whom bring well-established commercial, healthcare and military networks. TOMI’s long-term partner in Israel is also actively deploying SteraMist technology to support regional containment efforts in response to an active Ebola outbreak. In Puerto Rico, Integrated Services for Productivity and Validation (ISPV) is focused on driving adoption within the region’s strong life sciences and food manufacturing industries. In Argentina and surrounding markets, TOMI is collaborating with a new partner to pursue shared opportunities with major global accounts, including Pfizer, Fresenius Kabi, and Merck. This expansion complements the Company’s long-standing partnership with Bacteria Free in Chile, which is now extending its reach from life sciences into the food safety sector. NSF International (“NSF”) - an independent nonprofit organization of developed standards and certifies products for public health and safety - is rewriting the rules on Biosafety Cabinet (BSC) decontamination. TOMI played a key role in advancing discussion at the June 2026 meeting. The industry is shifting away from listing legacy known methods and brands, such as paraformaldehyde, and moving toward strict, performance-based criteria focused on efficacy, validation, and material compatibility areas where SteraMist iHP technology excels. Several high-quality opportunities within the pipeline underscore the strength of TOMI’s competitive positioning. These include a near-$1 million project initiated in Q2 involving the installation of four applicators per proprietary machine line at a major medical company, a large-scale opportunity now out for bid where our Canadian partners have secured access to supply eight Hybrid Systems, and a Custom Engineered System (“CES”) valued at approximately $1 million. TOMI continues to expand its presence in the defense sector, having recently received approvals from defense contractors in Korea and defense agencies in Canada. While confidentiality agreements limit the disclosure of specific details, these relationships represent multi-year efforts with significant long-term potential. The Company also remains actively engaged with key U.S. government agencies, including USAMRIID, NIH, Aberdeen, and others. In addition, TOMI, with a long-term representative of the company, will be helping implementation of a partnership with The Defense Logistics Agency (DLA), which manages the global defense supply chain for the U.S. military services and allied partners. This partnership is expected to streamline and accelerate government procurement of SteraMist iHP Techology. The Company will also be supporting the close of a pharmaceutical client who has received approvals for approximately $500,000 in SteraMist systems scheduled for delivery this year. TOMI’s Chief Operating Officer, Elissa J. (E.J.) Shane states, “We are pleased with the continued momentum across the SteraMist iHP business. With three consecutive quarters of growth, a quality pipeline, meaningful defense sector progress, and an expanding global partner network, TOMI is executing well on multiple fronts. We remain confident in the Company’s trajectory and believe we are well positioned for continued progress throughout the remainder of 2026 and beyond.” Dr. Halden Shane, Chairman and CEO of TOMI Environmental Solutions, commented, “This is an exciting period for our business and shareholders. In addition to the strong performance of TOMI’s business, the merger with Carbonium Core marks a strategic pivot into the high-growth nuclear materials sector, driven by demand from AI infrastructure and defense applications. Nuclear graphite is a critical, irreplaceable material for the future of clean energy, serving as a primary moderator, and structural component in next generation reactor design. It’s unique ability to withstand extreme temperature, provide structural stability, and efficiently slow down neutrons without absorbing them, makes it essential in obtaining nuclear chain reactions in advanced, safe, and efficient power systems. Demand for high purity nuclear graphite is accelerating rapidly due to the global push for decarbonization and energy security, with the International Energy Agency projecting that annual investment in nuclear projects will need to double to $120 billion by 2030”. For more information about SteraMist and TOMI Environmental Solutions, visit SteraMist.com. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to preliminary financial results, including preliminary revenue information, estimated open orders and sales pipeline, expected revenue growth in 2026 and beyond, the benefit of Carbonium merger; expectation with respect to Carbonium’s business operations; and the ability to TOMI to generate revenue in new and international markets. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These may include, but are not limited to, our ability to acquire new customers and expands sales; our projected revenue and revenue recognized from anticipated future purchase orders, invoiced orders, and contracts, our ability to maintain and manage growth and generate sales (equipment and consumable), our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT:John Nesbett/Zach NevasIMS Investor Relationstomi@imsinvestorrelations.com

A switch looks like the least of a medical device's design problems. It is small, well understood, and covered by a data sheet full of numbers, so it tends to get chosen late, once the electronics and the enclosure are settled. That habit is where a good share of cleaning-related field failures start. On a medical device, a switch is not only a component; it is a deliberate opening in an otherwise sealed instrument, sitting exactly where hands, gloves, fluids, and disinfectants reach the product. It must keep working through years of that. Specify it for the bench instead of for the clinical environment, and the decision comes back as an intermittent fault after cleaning, or as a usability problem caught in testing. The clinical environment is harsher than the data sheet assumes A data sheet describes behavior in a laboratory. The bedside and the operating room are not a laboratory. A device in use is wiped, sprayed, or immersed many times a day, often with harsh chemistries: sodium hypochlorite (bleach), quaternary ammonium compounds, alcohols, and hydrogen peroxide or peracetic acid. It is handled with gloved and sometimes wet hands, set down hard, and cleaned again. Over a service life measured in years, one control takes fluid ingress, chemical attack, and mechanical wear at the same time, and the switch, as the single intended gap in the housing, is usually what gives way first. The cleaning protocol a device must tolerate is not a detail to check at the end. It is the specification the control is chosen against. An ingress rating is necessary, and it is not the whole answer The obvious move is a sealed switch with a high ingress protection rating, and that instinct is right. What an IP code promises is narrower than it looks. Under IEC 60529, a rating like IP67 means the part kept dust out of a defined chamber and survived immersion to a set depth for a set time. Useful, and real. It says nothing about the disinfectant a given hospital uses, nothing about surviving hundreds of cleaning cycles rather than one immersion, and nothing about whether the surface a user touches can be cleaned. The IP class also encodes how the water arrived, and that matters more than the single number suggests. IPX7 is a static immersion test. It does not cover the powerful jets of IPX6, or the high-pressure, high-temperature spray of IPX9K. A device cleaned by immersion is well served by an immersion rating; a device blasted with a spray gun or steam is not, whatever its IPX7 mark says. Match the rating to how the device is cleaned, then ask for the test evidence behind it. Chemistry is the failure the rating does not describe The rating tells you a part survived water. Water is rarely the problem. The disinfectants are, and different chemistries attack different materials. Bleach oxidizes and can corrode exposed metals and degrade some elastomers; alcohols craze certain rigid plastics and dry out and harden some seals; quaternary ammonium compounds and hydrogen peroxide each have their own targets. The seal and actuator materials, not only the housing, decide how the switch ages under a cleaning regime. Silicone is a common choice for a sealed actuator because it holds up well to a broad range of hospital disinfectants and to the heat of repeated cycles, better than many thermoplastic elastomers, though even silicone must be confirmed against the specific agent and concentration a customer will use. Chemical compatibility belongs in the specification as its own line, verified over repeated exposure rather than inferred from an IP number. Sealing that survives immersion, shown rather than described "Sealed" should mean tested. A common and effective construction is a tactile switch closed by a silicone membrane, which keeps fluid out of the contact chamber while still passing the press through to the dome. Whether it works is a matter of evidence. Figure 1. A sealed tactile switch keeps fluid out of the contact chamber while a hand press still reaches the dome. A recessed button with a gap around the plunger lets fluid in and traps residue. A sealed tactile switch rated to IP6X and IPX7 was tested this way: 10 units were held under water at one meter for thirty minutes, then measured. Contact resistance sat in the mid-teens of milliohms before immersion and stayed there after, moving by no more than a few milliohms, and insulation resistance held above its threshold, with every unit passing. The number itself is not the point. The point is that sealing at the switch can be shown to leave the electrical contact untouched after immersion, and that a specification is entitled to ask for that proof instead of a word on a data sheet. Figure 2. Contact resistance of ten sealed units before and after immersion at one meter for thirty minutes (IP6X and IPX7). Every reading stayed far under the post-test limit. Figure 3. The silicone membrane seals from the tested sealed tactile switch, shown at 0.5x magnification. The seamless surface both keeps fluid out and wipes clean. Cleanability is a problem of surface geometry Keeping fluid out of the mechanism is half the job. The half that faces the user is cleanability, and it is not the same thing. A control that cannot be wiped clean is a reservoir for contamination, however well its inside is sealed. A smooth, continuous actuator surface, a sealed silicone membrane with no exposed seam, wipes down completely and leaves a disinfectant nowhere to sit. Recessed buttons, the gap around a bare plunger, and the crevice at a panel joint hold fluid and biofilm and resist reliable reprocessing. The surface a hand touches must be designed for cleaning, not only the internals for sealing. A switch can be sealed and still be hard to clean, and on a medical device that is a failure of its own. The force a gloved hand needs A medical control must be usable by the people who operate it, the way they operate it. Clinicians work in gloves, sometimes two pairs. They often act without looking, sometimes with one hand already full, and the user population runs down to older patients with limited dexterity on a home-use device. Sealing pushes against all of this. The silicone layer that keeps fluid out also adds resistance, raising the force to actuate and softening the click that confirms it. A sealed control still must fire at a low, repeatable force and return a clear tactile signal through a glove, so the user knows the press landed without watching for it. Under IEC 62366-1 this is not a comfort question but a use-error one: an actuation that is heavy, mushy, or easy to miss produces exactly the kind of use error a usability file is meant to catch. Where more than one actuation force is available, the lighter, more repeatable option should be specified deliberately for gloved and lower dexterity use rather than left to a heavier default. Reliability is two clocks A switch on a medical device runs against two clocks, and a data sheet usually shows one. The first is mechanical life, the rated operations, which must be measured against how often the control is really pressed over the device's service life, not taken as generous. The second is reprocessing durability, how many cleaning and disinfection cycles the seal and surfaces survive against their chemistry. It is a different number, and often it is not printed anywhere. A switch good for tens of thousands of presses can still fail early when its seal gives out under the cleaning agent long before those presses are spent. Both clocks belong in the specification, and the reprocessing one has to be asked for by name, because it will not appear on its own. Specifying on evidence The reliable way to choose a medical control is to fix the environment first and let the component follow. Start from the reprocessing instructions the device will carry: which disinfectants, applied by wipe, spray, or immersion, and how often. Require an ingress rating that matches that method, not just a high one, and ask for the test evidence behind it. Confirm the seal and actuator materials against the specific chemistries, over repeated cycles. Specify a low, repeatable actuation force and clear tactile feedback so the control works gloved, one-handed, and for lower-dexterity users. Check rated mechanical life against the real duty and write cleaning durability in as its own requirement. Then choose the switch that meets the evidence, not the one that reads best on paper. Figure 4. Specifying a medical control from the reprocessing environment, then choosing on test evidence. The small part with the large risk A user control is a small part that carries an outsized share of a medical device's clinical and regulatory risk, because it sits where the user, the fluids, and the disinfectants all reach the product together. Left as an afterthought, it becomes the reason a device is cleaned and then will not respond, or the finding that sends a design back for another usability round. Chosen for the reprocessing environment and the gloved hand and backed by test evidence rather than a claim on a data sheet, it holds up for the life of the device and asks for no further attention. That is the whole of what a good control is supposed to do.